Drug targeting in Leishmania donovani infections using tuftsin-bearing liposomes as drug vehicles.
The efficacy of sodium stibogluconate against Leishmania donovani infections was markedly enhanced by encapsulating this drug in tuftsin-bearing liposomes. Also, pretreatment of the animals with these liposomes (free of drug) rendered them resistant to this infection, possibly by activating the host's macrophages. These results demonstrate that tuftsin-bearing liposomes besides delivering the drug to the target cells could also enhance the nonspecific resistance against infections, thus offering an additional advantage over the use of tuftsin-free liposomes as drug carriers in leishmania therapy.
Guru
P Y
PY
Division of Membrane Biology, Central Drug Research Institute, Lucknow, India.
Agrawal
A K
AK
Singha
U K
UK
Singhal
A
A
Gupta
C M
CM
D000276:Adjuvants, Immunologic; D000818:Animals; D000967:Antimony Sodium Gluconate / Q000008:administration & dosage* / Q000627:therapeutic use; D006224:Cricetinae; D004337:Drug Carriers; D005942:Gluconates / Q000008:administration & dosage*; D007893:Leishmania donovani; D007898:Leishmaniasis, Visceral / Q000188:drug therapy* / Q000276:immunology; D008081:Liposomes / Q000276:immunology; D008264:Macrophages / Q000276:immunology; D008297:Male; D008647:Mesocricetus; D051379:Mice; D008807:Mice, Inbred BALB C; D014405:Tuftsin / Q000276:immunology
D000276:Adjuvants, Immunologic; D004337:Drug Carriers; D005942:Gluconates; D008081:Liposomes; D014405:Tuftsin; D000967:Antimony Sodium Gluconate